Indications and uses
For use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.
For use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.
Usual Dosage: One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.
Each Anusol-HC® 25 mg Suppository contains 25 mg hydrocortisone acetate in a hydrogenated vegetable oil base. Hydrocortisone acetate is a corticosteroid. Chemically, hydrocortisone acetate is pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy (11β)- with the following structural formula:
In normal subjects, about 26 percent of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.
Topical steroids are primarily effective because of their anti-inflammatory, anti-pruritic and vasoconstrictive action.
For use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.
Anusol-HC® suppositories are contraindicated in those patients with a history of hypersensitivity to any of the components.
Do not use unless adequate proctologic examination is made.
If irritation develops, the product should be discontinued and appropriate therapy instituted.
In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.
Staining of fabric may occur with use of the suppository. Precautionary measures are recommended.
In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women. Anusol-HC® suppositories should only be used during pregnancy if the potential benefit justifies the risk of the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Nursing Mothers:
It is not known whether this drug is excreted in human milk, and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Anusol-HC® suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The following local adverse reactions have been reported with corticosteroid suppositories.
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Drug abuse and dependence has not been reported in patients treated with Anusol-HC® suppositories.
If signs and symptoms of systemic overdosage occur, discontinue use.
Usual Dosage: One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.
Anusol-HC® 25 mg Suppositories are white, cylinder shaped, with one end tapered.
NDC 65649-411-12 25 mg 12 suppositories
NDC 65649-411-24 25 mg 24 suppositories
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Store away from heat. PROTECT FROM FREEZING.
Distributed by: Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ 08807 USA
Anusol-HC is a trademark of Salix Pharmaceuticals, Inc. or its affiliates.
© 2024 Salix Pharmaceuticals, Inc. or its affiliates
OPENING INSTRUCTIONS
Avoid excessive handling of the suppository. It is designed to melt at body temperature.
1. Separate plastic film at top opening and pull downward.
2. Continue pulling downward to almost the full length of the suppository.
3. Gently remove the suppository from the film pocket.
Rev. 07/2024
9520702
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1291103 | Anusol-HC 25 MG Rectal Suppository | PSN | 7 |
| 1291082 | hydrocortisone acetate 25 MG Rectal Suppository | PSN | 7 |
| 1291103 | hydrocortisone acetate 25 MG Rectal Suppository [Anusol HC] | SBD | 7 |
| 1291082 | hydrocortisone acetate 25 MG Rectal Suppository | SCD | 7 |
| 1291103 | Anusol HC 25 MG Rectal Suppository | SY | 7 |
| Class | Version | Type | Effective |
|---|---|---|---|
| HYDROCORTISONE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 65649-411-12 | Anusol HC | 12 in 1 BOX | SUPPOSITORY | 12 | 7 | |
| 65649-411-24 | Anusol HC | 24 in 1 BOX | SUPPOSITORY | 24 | 7 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 65649-411-12 | EA - Each | 65649-411 | 9c5ccebb-b2c0-4ea4-999d-fd91b05ddfeb | 1 | 2012-07-24 |
| 65649-411-24 | EA - Each | 65649-411 | 0359f684-4a35-4f37-bd22-4ae453800e63 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| HYDROCORTISONE ACETATE | ACTIVE INGREDIENT | 3X7931PO74 | 3 | |
| HYDROCORTISONE | ACTIVE MOIETY | WI4X0X7BPJ | 3 | |
| BUTYLATED HYDROXYANISOLE | INACTIVE INGREDIENT | REK4960K2U | 3 | |
| HYDROGENATED PALM OIL | INACTIVE INGREDIENT | 257THB963H | 3 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 65649-411 | 65649-411-12, 65649-411-24 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYDROCORTISONE ACETATE | 3X7931PO74 | ACTIB |
| HYDROGENATED PALM OIL | 257THB963H | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| BUTYLATED HYDROXYANISOLE | REK4960K2U | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | SUPPOSITORY / RECTAL | 1 mg | ||
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | SUPPOSITORY / RECTAL | 1 mg | ||
| HYDROGENATED PALM OIL | HYDROGENATED PALM OIL | 257THB963H | SUPPOSITORY / RECTAL | NA | ||
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | SUPPOSITORY / RECTAL | 1 mg | ||
| HYDROGENATED PALM OIL | HYDROGENATED PALM OIL | 257THB963H | SUPPOSITORY / RECTAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| HYDROGENATED PALM OIL | HYDROGENATED PALM OIL | 257THB963H | SUPPOSITORY / RECTAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anusol HC | HYDROCORTISONE ACETATE | Salix Pharmaceuticals, Inc | a562f3d7-2692-4357-aade-ae50afcbfddd | 2024-07-01 | Adverse reactions | 65649-411-12 65649-411-24 65649-411 65649041112 65649041124 3bb1affd-e321-496d-8bec-0feb8cc15e51 a562f3d7-2692-4357-aade-ae50afcbfddd |
Adverse event summaries are temporarily unavailable. Other product information remains available.